20 (AIDX) Current Deferred Revenue (2024 - 2026)

20 (AIDX) reported Current Deferred Revenue of $450667.0 for Q1 2026, down 1.32% quarter-over-quarter from $456687.0 in Q4 2025.

20 (AIDX) Current Deferred Revenue (2024 - 2026) Analysis & Trends

20 has reported Current Deferred Revenue for 3 years, with the latest figure at $450667.0 in Q1 2026.

  • For the quarter ending Q1 2026, Current Deferred Revenue changed N/A year-over-year to $450667.0; the trailing twelve-month figure through Mar 2026 stood at $450667.0 (changed N/A YoY), and the FY2025 full-year result was $456687.0, down 2.93% from the prior year.
  • Current Deferred Revenue for Q1 2026 stood at $450667.0, down from $456687.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $470451.0 in Q4 2024, with the low at $450667.0 in Q1 2026.
  • Historically, Current Deferred Revenue has averaged $459268.3 across 3 years, with a median of $456687.0 in 2025.
  • The largest YoY upside for Current Deferred Revenue was 2.93% in 2025 against a maximum downside of 2.93% in 2025.
  • 20's Current Deferred Revenue stood at $470451.0 in 2024, then dropped by 2.93% to $456687.0 in 2025, then declined by 1.32% to $450667.0 in 2026.
  • The last three Current Deferred Revenue figures came in at $450667.0 (Q1 2026), $456687.0 (Q4 2025), and $470451.0 (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn
10 20 - - 62,884.00

Historic Data

Download Data
DateValue
Mar 31, 2026 450,667.00
Dec 31, 2025 456,687.00
Dec 31, 2024 470,451.00